Random Survival Forest Predicts Survival in Patients with Metastatic Laryngeal and Hypopharyngeal Cancer and the Prognostic Benefits of Surgery and Radiotherapy

Overview

Journal J Cancer

Specialty Oncology

Date 2025 Jan 2

PMID 39744488

Authors

Yusheng Wang

Chaofan Li

Feilun Yang

Minjie Gong

Jingkun Qu

Ruiping Ma

Zhenzhen Hu

Miao Lou

Xiaoyong Ren

Guoxi Zheng

Yanxia Bai

Ya Zhang

Jin Hou

Affiliations

Soon will be listed here.

Abstract

Laryngeal and hypopharyngeal cancers are prominent within head and neck malignancies. The diagnosis of distant metastasis (DM) invariably signals poor prognosis, underscoring the need to optimize current treatment approaches. Patient data for metastatic laryngeal and hypopharyngeal cancer were extracted from the SEER database (2000-2020). Cox regression and propensity score matching (PSM) analyses identified independent prognostic factors and performed stratified survival analyses based on the receipt of primary tumor surgery and radiotherapy. A random survival forest (RSF) model was subsequently developed to predict patient survival. A total of 1,626 patients were included. PSM-based stratified analysis revealed that primary tumor surgery significantly improved survival in patients under 70 years and those with primary laryngeal cancer. Radiotherapy enhanced survival across all age groups, with a benefit primarily for patients with primary laryngeal cancer and squamous-cell carcinoma (SCC). The RSF model demonstrated robust predictive performance, highlighting chemotherapy, primary tumor surgery, and radiotherapy as the top three factors influencing patient survival. The clinical and pathological features of metastatic laryngeal/hypopharyngeal cancer were systematically analyzed using an artificial intelligence (AI) model to predict survival. Subgroup analyses identified patients most likely to benefit from primary tumor surgery and radiotherapy. These findings may guide the development of personalized treatment strategies, potentially improving the prognosis of patients with DM.

References

Cannon R, Carpenter P, Boothe D, Buchmann L, Hunt J, Lloyd S . Academic Facility Utilization and Survival Outcomes in Adult Head and Neck Sarcomas: An NCDB Analysis. Otolaryngol Head Neck Surg. 2018; 159(3):473-483. DOI: 10.1177/0194599818768495. View

Plichta J, Thomas S, Hayes D, Chavez-MacGregor M, Allison K, De los Santos J . Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer. J Clin Oncol. 2023; 41(14):2546-2560. PMC: 10414698. DOI: 10.1200/JCO.22.02222. View

Florescu C, Thariat J . Local ablative treatments of oligometastases from head and neck carcinomas. Crit Rev Oncol Hematol. 2014; 91(1):47-63. DOI: 10.1016/j.critrevonc.2014.01.004. View

Bonomo P, Greto D, Desideri I, Loi M, Di Cataldo V, Orlandi E . Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?. Oral Oncol. 2019; 93:1-7. DOI: 10.1016/j.oraloncology.2019.04.006. View

Huang S, OSullivan B, Waldron J, Lockwood G, Bayley A, Kim J . Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. Int J Radiat Oncol Biol Phys. 2010; 79(1):46-51. DOI: 10.1016/j.ijrobp.2009.10.052. View

Michiels S, Le Maitre A, Buyse M, Burzykowski T, Maillard E, Bogaerts J . Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009; 10(4):341-50. DOI: 10.1016/S1470-2045(09)70023-3. View

Yoshida K, Hernandez-Diaz S, Solomon D, Jackson J, Gagne J, Glynn R . Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. Epidemiology. 2017; 28(3):387-395. PMC: 5378668. DOI: 10.1097/EDE.0000000000000627. View

Grover S, Swisher-McClure S, Mitra N, Li J, Cohen R, Ahn P . Total Laryngectomy Versus Larynx Preservation for T4a Larynx Cancer: Patterns of Care and Survival Outcomes. Int J Radiat Oncol Biol Phys. 2015; 92(3):594-601. DOI: 10.1016/j.ijrobp.2015.03.004. View

Shan Sun X, Michel C, Babin E, De Raucourt D, Pechery A, Gherga E . Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. Future Oncol. 2018; 14(9):877-889. DOI: 10.2217/fon-2017-0468. View

10.

Pan Y, Hong Y, Liang Z, Zhuang W . Survival analysis of distant metastasis of laryngeal carcinoma: analysis based on SEER database. Eur Arch Otorhinolaryngol. 2018; 276(1):193-201. DOI: 10.1007/s00405-018-5244-5. View

11.

Cattaruzza M, Maisonneuve P, Boyle P . Epidemiology of laryngeal cancer. Eur J Cancer B Oral Oncol. 1996; 32B(5):293-305. DOI: 10.1016/0964-1955(96)00002-4. View

12.

Li C, Hui Y, Wei X, Yao P, Jia Y, Liu M . Visualized machine learning models combined with propensity score matching analysis in single PR-positive breast cancer prognosis: a multicenter population-based study. Am J Cancer Res. 2023; 13(6):2234-2253. PMC: 10326595. View

13.

Li X, Di B, Shang Y, Zhou Y, Cheng J, He Z . Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas. Eur J Surg Oncol. 2009; 35(12):1348-53. DOI: 10.1016/j.ejso.2009.06.010. View

14.

Myssiorek D, Rinaldo A, Barnes L, Ferlito A . Laryngeal paraganglioma: an updated critical review. Acta Otolaryngol. 2004; 124(9):995-9. DOI: 10.1080/00016480410017576. View

15.

Harrell Jr F, Califf R, Pryor D, Lee K, Rosati R . Evaluating the yield of medical tests. JAMA. 1982; 247(18):2543-6. View

16.

Vermorken J, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M . Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357(17):1695-704. DOI: 10.1056/NEJMoa071028. View

17.

DallOlio F, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N . Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 19(2):75-90. DOI: 10.1038/s41571-021-00564-3. View

18.

Pointer K, Ko H, Brower J, Witek M, Kimple R, Lloyd R . Small cell carcinoma of the head and neck: An analysis of the National Cancer Database. Oral Oncol. 2017; 69:92-98. PMC: 5553627. DOI: 10.1016/j.oraloncology.2017.04.009. View

19.

Li C, Liu M, Zhang Y, Wang Y, Li J, Sun S . Novel models by machine learning to predict prognosis of breast cancer brain metastases. J Transl Med. 2023; 21(1):404. PMC: 10286496. DOI: 10.1186/s12967-023-04277-2. View

20.

Li C, Liu M, Li J, Zhao X, Wang Y, Chen X . Relationship between metastasis and second primary cancers in women with breast cancer. Front Oncol. 2022; 12:942320. PMC: 9556865. DOI: 10.3389/fonc.2022.942320. View